DD143730A5 - Verfahren zur herstellung eines mittels zur verringerung des phenylalaningehaltes - Google Patents

Verfahren zur herstellung eines mittels zur verringerung des phenylalaningehaltes Download PDF

Info

Publication number: DD143730A5
Authority: DD; German Democratic Republic
Prior art keywords: phenylalanine; content; reducing; enzyme; alantse
Prior art date: 1978-05-12

Application number

DD79212783A

Other languages

German (de)

English (en)

Inventor

Walter Marconi

Francesco Bartoli

Robert Gianna

Franco Morisi

Giuseppina Spotorno

Original Assignee

Snam Progetti

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-05-12

Filing date

1979-05-10

Publication date

1980-09-10

1979-05-10 Application filed by Snam Progetti filed Critical Snam Progetti

1980-09-10 Publication of DD143730A5 publication Critical patent/DD143730A5/de

Links

238000004519 manufacturing process Methods 0.000 title description 2
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 27
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 27
239000008280 blood Substances 0.000 claims description 10
210000004369 blood Anatomy 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 8
239000000835 fiber Substances 0.000 claims description 8
229920002284 Cellulose triacetate Polymers 0.000 claims description 5
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims description 5
238000000034 method Methods 0.000 claims description 5
208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 3
108090000673 Ammonia-Lyases Proteins 0.000 claims description 2
102000004118 Ammonia-Lyases Human genes 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
DAVOZYNLPXEIEH-UHFFFAOYSA-N aniline;azane Chemical compound N.NC1=CC=CC=C1 DAVOZYNLPXEIEH-UHFFFAOYSA-N 0.000 claims 1
102000004190 Enzymes Human genes 0.000 description 13
108090000790 Enzymes Proteins 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 7
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
BTNMPGBKDVTSJY-UHFFFAOYSA-N keto-phenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-N 0.000 description 6
239000000243 solution Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
201000011252 Phenylketonuria Diseases 0.000 description 4
239000003531 protein hydrolysate Substances 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
239000001903 2-oxo-3-phenylpropanoic acid Substances 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
108010009736 Protein Hydrolysates Proteins 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
DEDGUGJNLNLJSR-UHFFFAOYSA-N alpha-hydroxycinnamic acid Natural products OC(=O)C(O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000000126 substance Substances 0.000 description 3
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000001635 urinary tract Anatomy 0.000 description 2
DGTOSJBLQULTIR-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanoic acid;hydrazine Chemical compound NN.OC(=O)[C@@H](N)CC1=CC=CC=C1 DGTOSJBLQULTIR-QRPNPIFTSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
RSTKLPZEZYGQPY-UHFFFAOYSA-N 3-(indol-3-yl)pyruvic acid Chemical compound C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1 RSTKLPZEZYGQPY-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
229940000681 5-hydroxytryptophan Drugs 0.000 description 1
102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
108700023158 Phenylalanine ammonia-lyases Proteins 0.000 description 1
102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
241000223253 Rhodotorula glutinis Species 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000003425 Tyrosinase Human genes 0.000 description 1
108060008724 Tyrosinase Proteins 0.000 description 1
108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000003925 brain function Effects 0.000 description 1
230000006652 catabolic pathway Effects 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
229960005219 gentisic acid Drugs 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
239000003617 indole-3-acetic acid Substances 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000036630 mental development Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000002182 neurohumoral effect Effects 0.000 description 1
230000001453 nonthrombogenic effect Effects 0.000 description 1
LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000005891 transamination reaction Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Vascular Medicine (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Heart & Thoracic Surgery (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Polymers & Plastics (AREA)
Microbiology (AREA)
Dispersion Chemistry (AREA)
Anesthesiology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Nutrition Science (AREA)
Food Science & Technology (AREA)
Obesity (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
External Artificial Organs (AREA)

DD79212783A 1978-05-12 1979-05-10 Verfahren zur herstellung eines mittels zur verringerung des phenylalaningehaltes DD143730A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT23336/78A IT1096208B (it)	1978-05-12	1978-05-12	Composizione adatta alla riduzione del tenore di fenilalanina e metodo impiegante la stessa

Publications (1)

Publication Number	Publication Date
DD143730A5 true DD143730A5 (de)	1980-09-10

Family

ID=11206197

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD79212783A DD143730A5 (de)	1978-05-12	1979-05-10	Verfahren zur herstellung eines mittels zur verringerung des phenylalaningehaltes

Country Status (19)

Country	Link
US (1)	US4248704A (fr)
JP (1)	JPS54147909A (fr)
AU (1)	AU521742B2 (fr)
BE (1)	BE876204A (fr)
CA (1)	CA1130206A (fr)
CS (1)	CS214795B2 (fr)
DD (1)	DD143730A5 (fr)
DE (1)	DE2919127C2 (fr)
DK (1)	DK182479A (fr)
FR (1)	FR2425246A1 (fr)
GB (1)	GB2020668B (fr)
HU (1)	HU181954B (fr)
IL (1)	IL57251A (fr)
IT (1)	IT1096208B (fr)
LU (1)	LU81242A1 (fr)
NL (1)	NL7903789A (fr)
NO (1)	NO791557L (fr)
SE (1)	SE7904161L (fr)
ZA (1)	ZA792249B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU194487B (en) *	1979-12-28	1988-02-29	Chinoin Gyogyszer Es Vegyeszet	Process for producing food-preparation suitable for feeding sicks of phenylketoneurea from protein hydrolysates
DE3167008D1 (en)	1980-02-13	1984-12-13	Sorin Biomedica Spa	Method of immobilizing an enzyme in a bundle of cellulosic fibres for a fibre-bundle dialyzer for purifying blood
JPS56145857A (en) *	1980-04-15	1981-11-12	Unitika Ltd	Material for purifying body fluid and its manufacture
US4562151A (en) *	1983-09-06	1985-12-31	Monsanto Company	Stabilization of L-phenylalanine ammonia-lyase enzyme
JPS61353A (ja) *	1984-06-13	1986-01-06	テルモ株式会社	薬剤投与装置
JPH0655223B2 (ja) *	1986-05-06	1994-07-27	宇部興産株式会社	非生物学的吸着剤
US4955857A (en) *	1988-07-18	1990-09-11	Shettigar Udipi R	Multi-enzyme bioreactor therapy for cancer
US5324253A (en) *	1992-03-02	1994-06-28	Mcrea James C	Cannula apparatus and system for heparin removal from blood
DK75593D0 (fr) *	1993-06-25	1993-06-25	Novo Nordisk As
ATE203171T1 (de) *	1993-08-10	2001-08-15	Slobodan Tepic	Gerät zum behandeln von tumoren mittels selektiver proteinverringerung
US5868936A (en) *	1996-06-20	1999-02-09	Baxter International Inc.	Affinity membrane system and method of using same
CN116114787A (zh) *	2023-03-16	2023-05-16	中国农业科学院农产品加工研究所	一种高效脱除蛋白原料中苯丙氨酸的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE123476C (fr) *	1960-09-19
US3441142A (en) *	1966-07-21	1969-04-29	Dow Chemical Co	Nonthrombogenic plastic membranes
US3522346A (en) *	1968-05-31	1970-07-28	Research Corp	Nonthrombogenic microcapsules
IL32406A (en) *	1968-06-26	1973-01-30	Snam Progetti	Enzyme preparations comprising a solution or dispersion of enzyme occluded in filaments of cellulose esters or synthetic polymers
US3673612A (en) *	1970-08-28	1972-07-04	Massachusetts Inst Technology	Non-thrombogenic materials and methods for their preparation
US3809613A (en) *	1971-05-28	1974-05-07	Research Corp	Biocatalytic module
JPS5136810B2 (fr) *	1972-08-04	1976-10-12
US4004980A (en) *	1975-03-25	1977-01-25	Purdue Research Foundation	Enzyme entrappment with cellulose acetate formulations
US4051040A (en) *	1976-03-17	1977-09-27	John L. Hutchinson	Antithrombogenic hemo dialysis membranes
JPS5340691A (en) *	1976-04-01	1978-04-13	Korufu Fuaundeeshiyon Za	Method and apparatus for removing impurities from fluids
IT1085524B (it) *	1977-03-22	1985-05-28	Snam Progetti	Materiali e fibre porose biocompatibili in grado di inglobare sostanze di interesse biologico e metodi per il loro ottenimento

1978
- 1978-05-12 IT IT23336/78A patent/IT1096208B/it active
1979
- 1979-05-03 DK DK182579A patent/DK182479A/da unknown
- 1979-05-03 US US06/035,528 patent/US4248704A/en not_active Expired - Lifetime
- 1979-05-09 ZA ZA792249A patent/ZA792249B/xx unknown
- 1979-05-09 NO NO791557A patent/NO791557L/no unknown
- 1979-05-09 AU AU46895/79A patent/AU521742B2/en not_active Ceased
- 1979-05-09 GB GB7916059A patent/GB2020668B/en not_active Expired
- 1979-05-10 FR FR7911923A patent/FR2425246A1/fr active Granted
- 1979-05-10 DD DD79212783A patent/DD143730A5/de unknown
- 1979-05-10 LU LU81242A patent/LU81242A1/fr unknown
- 1979-05-11 HU HU79SA3181A patent/HU181954B/hu unknown
- 1979-05-11 BE BE0/195119A patent/BE876204A/fr not_active IP Right Cessation
- 1979-05-11 CA CA327,577A patent/CA1130206A/fr not_active Expired
- 1979-05-11 JP JP5718979A patent/JPS54147909A/ja active Pending
- 1979-05-11 SE SE7904161A patent/SE7904161L/ not_active Application Discontinuation
- 1979-05-11 DE DE2919127A patent/DE2919127C2/de not_active Expired
- 1979-05-11 IL IL57251A patent/IL57251A/xx unknown
- 1979-05-12 CS CS793256A patent/CS214795B2/cs unknown
- 1979-05-14 NL NL7903789A patent/NL7903789A/xx not_active Application Discontinuation

Also Published As

Publication number	Publication date
IT1096208B (it)	1985-08-26
JPS54147909A (en)	1979-11-19
DK182479A (da)	1979-11-13
US4248704A (en)	1981-02-03
AU521742B2 (en)	1982-04-29
DE2919127C2 (de)	1982-10-21
BE876204A (fr)	1979-11-12
SE7904161L (sv)	1979-11-13
CA1130206A (fr)	1982-08-24
ZA792249B (en)	1980-05-28
GB2020668A (en)	1979-11-21
NO791557L (no)	1979-11-13
FR2425246A1 (fr)	1979-12-07
AU4689579A (en)	1979-11-15
LU81242A1 (fr)	1979-09-10
DE2919127A1 (de)	1979-11-22
IL57251A (en)	1982-04-30
GB2020668B (en)	1982-09-08
IT7823336A0 (it)	1978-05-12
FR2425246B1 (fr)	1983-08-05
NL7903789A (nl)	1979-11-14
IL57251A0 (en)	1979-09-30
CS214795B2 (en)	1982-05-28
HU181954B (en)	1983-11-28

Publication	Publication Date	Title
DE69831869T2 (de)	2006-07-13	Verbesserte verabreichungstechnik für multiple medikamentengaben
DE3751860T2 (de)	1996-11-21	Verwendung von spezifischem Kernmaterial und Schichten zur Herstellung pharmazeutischer Formulierungen, die stabil gegen die Verfärbung von Omeprazol sind
EP0032562B1 (fr)	1984-03-14	Formes-retard pour l'administration du dipyridamol et procédés pour leur préparation
DD143730A5 (de)	1980-09-10	Verfahren zur herstellung eines mittels zur verringerung des phenylalaningehaltes
EP0519870B1 (fr)	1996-09-11	Nouvelle composition à base de diclofenac pour l'administration orale
DE69423028T3 (de)	2006-07-20	Zubereitung mit kontrollierter freisetzung, die ein morphinsalz enthält
DE69434911T2 (de)	2007-08-30	Opioid-Formulierungen zur Schmerzbehandlung
DE220143T1 (de)	1989-01-26	Pharmazeutische zubereitungen von metoprolol mit kontrollierter wirkstoff abgabe, verfahren zu ihrer herstellung und verwendung dieser zubereitungen.
KR910005875A (ko)	1991-04-27	미노시클린을 위한 일일-1회 투여 제약학적 조달 계 및 그의 제조방법
DE3815562A1 (de)	1988-11-24	Pharmazeutische zusammensetzung
Watanabe et al.	1981	Edematous necrosis in thiamine-deficient encephalopathy of the mouse
DE10202487A1 (de)	2003-07-31	Dermales Applikationssystem für Aminolävulinsäure-Derivate
DE69327745T2 (de)	2000-09-21	Tablette zur langsamen Freisetzung von Natriumvalproat
EP0561821B1 (fr)	1994-12-28	Procede d'obtention de particules de collagene et leur utilisation comme support de matiere active
DE68907177T2 (de)	1994-01-13	Dosierungsform.
DE4140179C2 (de)	1995-12-21	Akutform für ein Ibuprofen enthaltendes Arzneimittel
EP0349453A1 (fr)	1990-01-03	Nouvelle forme pharmaceutique à libération prolongée à base d'un complexe résine-principe actif
DE2612726B2 (de)	1978-07-06	Stabilisierte Urease
DE2752728C2 (de)	1985-08-01	Pharmazeutische Zubereitung mit verzögerter Abgabe
DE3446887C2 (de)	1994-05-05	Verfahren zur Herstellung von physiologisch aktivem, wasserlöslichem Hämin-arginat bzw. Hämin-lysinat
DE69815306T2 (de)	2004-04-29	Valnoctamid-stereoisomere, eine methode zu ihrer herstellung und abtrennung und ihre anwendungen
RU2382636C2 (ru)	2010-02-27	Композиция сиропа, включающая дексибупропен в качестве активного ингредиента, и способ ее получения
DE2946563C2 (de)	1987-04-30	Aminosäurelösung zur parenteralen Infusion
DE3019895C2 (fr)	1987-10-29
DE3016548A1 (de)	1981-04-16	Verfahren zur herabsetzung der thermischen stabilitaet von mikrobiellem mucor-rennin und dessen verwendung zur kaesebereitung